3D打印药品要来了！全国首证宁企到手！

Group 1 - The first 3D printed drug in China is nearing market launch, with the Jiangsu Provincial Drug Administration issuing the first production license for 3D printed pharmaceuticals to Nanjing Sanjieji Pharmaceutical Technology Co., Ltd [1] - 3D printing technology, also known as additive manufacturing, offers higher production efficiency and the ability to create complex internal structures compared to traditional manufacturing methods [1] - The MED (Melt Extrusion Deposition) 3D printing technology developed by Sanjieji allows for controlled drug release, efficient formulation development, and high-quality intelligent manufacturing, enhancing drug efficacy and reducing side effects [1] Group 2 - Following the production license, Sanjieji's first 3D printed drug, Apixaban tablets (T20j), is ready for market registration, targeting treatment for venous thromboembolism [2] - Sanjieji plans to submit the market application to the National Medical Products Administration (NMPA) in September, supported by the Jiangsu Provincial Drug Administration [2] - Founded in July 2015, Sanjieji is a leader in the global 3D printed drug sector, holding the largest production capacity and a patent portfolio exceeding 20% in the field [2]